Recent Quotes (30 days)

You have no recent quotes
chg | %

Catalyst Biosciences Inc  

(Public, NASDAQ:CBIO)   Watch this stock  
Find more results for CBIO
10.49
+0.56 (5.64%)
Dec 15 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 9.80 - 10.65
52 week 3.11 - 18.88
Open 10.00
Vol / Avg. 376,845.00/433,312.00
Mkt cap 47.77M
P/E     -
Div/yield     -
EPS -13.12
Shares 4.31M
Beta 1.94
Inst. own 35%
Mar 6, 2018
Q4 2017 Catalyst Biosciences Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Nov 2, 2017
Q3 2017 Catalyst Biosciences Inc Earnings Release
Sep 26, 2017
Catalyst Biosciences Inc at Ladenburg Thalmann Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin -1821.70% -4246.87%
Operating margin -1848.43% -5117.29%
EBITD margin - -5017.04%
Return on average assets -62.78% -31.49%
Return on average equity -84.14% -71.35%
Employees 10 -
CDP Score - -

Address

260 Littlefield Ave
SOUTH SAN FRANCISCO, CA 94080-6902
United States - Map
+1-650-7450655 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Catalyst Biosciences, Inc., formerly Targacept, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function (DGF) in renal transplants and the treatment of dry age-related macular degeneration (dry AMD), a condition that can cause visual impairment or blindness. The Company's advanced program is a coagulation Factor VIIa variant, CB 813d, that has completed a Phase I clinical trial in severe hemophilia A and B patients. In addition to its lead Factor VIIa program, it has approximately two other coagulation factors, a Factor IX variant, CB 2679d/ISU 304, that is in advanced preclinical development, and a Factor Xa variant that has reached the advanced lead preclinical-stage of development.

Officers and directors

Nassim Usman Ph.D. President, Chief Executive Officer, Director
Age: 51
Bio & Compensation  - Reuters
Fletcher Payne Chief Financial Officer
Bio & Compensation  - Reuters
Andrew Hetherington Vice President - Manufacturing Operations
Bio & Compensation  - Reuters
Arwa Shurrab Vice President - Regulatory Affairs
Bio & Compensation  - Reuters
Jeffrey Landau Vice President - Business Development
Bio & Compensation  - Reuters
Howard Levy Ph.D. Chief Medical Officer
Bio & Compensation  - Reuters
Jamie Siegel M.D. Head - Clinical Development
Bio & Compensation  - Reuters
Errol B. De Souza Ph.D. Director
Age: 63
Bio & Compensation  - Reuters
Stephen Anthony Hill M.D. Director
Age: 59
Bio & Compensation  - Reuters
Jeffrey Himawan Ph.D. Director
Age: 52
Bio & Compensation  - Reuters